Nyxoah (NASDAQ:NYXH) Price Target Lowered to $19.00 at Stifel Nicolaus

Nyxoah (NASDAQ:NYXH) had its price target decreased by equities research analysts at Stifel Nicolaus from $27.00 to $19.00 in a report issued on Monday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. Stifel Nicolaus’ price objective points to a potential upside of 126.73% from the stock’s previous close.

Several other equities analysts also recently commented on NYXH. Cantor Fitzgerald lowered their price objective on shares of Nyxoah from $18.00 to $17.00 and set an “overweight” rating for the company in a research note on Wednesday, May 15th. HC Wainwright lowered their price objective on shares of Nyxoah from $22.00 to $18.00 and set a “buy” rating for the company in a research note on Friday, May 24th. Piper Sandler upped their price objective on shares of Nyxoah from $15.00 to $20.00 and gave the company an “overweight” rating in a research note on Wednesday, March 6th. Finally, Oppenheimer lowered their price objective on shares of Nyxoah from $20.00 to $15.00 and set an “outperform” rating for the company in a research note on Wednesday, May 15th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $17.80.

Nyxoah Price Performance

NYXH opened at $8.38 on Monday. The company has a fifty day moving average price of $9.33 and a 200-day moving average price of $9.77. The company has a debt-to-equity ratio of 0.13, a quick ratio of 3.70 and a current ratio of 3.94. Nyxoah has a one year low of $4.00 and a one year high of $20.00.

Nyxoah (NASDAQ:NYXH) last released its quarterly earnings results on Tuesday, May 14th. The company reported ($0.45) EPS for the quarter, meeting analysts’ consensus estimates of ($0.45). The firm had revenue of $1.33 million during the quarter, compared to analyst estimates of $1.20 million. Nyxoah had a negative net margin of 843.49% and a negative return on equity of 42.14%. Sell-side analysts anticipate that Nyxoah will post -1.69 EPS for the current year.

Hedge Funds Weigh In On Nyxoah

A hedge fund recently bought a new stake in Nyxoah stock. Ikarian Capital LLC acquired a new position in Nyxoah S.A. (NASDAQ:NYXH) during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 50,699 shares of the company’s stock, valued at approximately $684,000.

About Nyxoah

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.